Related Experiment Video

Updated: Nov 10, 2025

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
07:35

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer

Published on: December 26, 2016

42.0K

Molecular Mechanism of Secondary Endocrine Resistance in Luminal Breast Cancer

Minhua Wu1, Jinhua Ding1, Limu Wen1

  • 1Li Huili Hospital, Ningbo Medical Center, Ningbo 315040, China.

Biomed Research International
|April 5, 2021
PubMed
Abstract

Insights

Myeloid leukemia factor 1-interacting proteins (MLF1IP) downregulation enhances breast cancer cell sensitivity to Tamoxifen by promoting apoptosis. MLF1IP inhibition of PTEN activates AKT, driving secondary resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Secondary resistance to endocrine therapy is a major challenge in treating Luminal breast cancer.
  • Understanding the molecular mechanisms underlying this resistance is crucial for developing effective treatment strategies.

Purpose of the Study:

  • To investigate the role of myeloid leukemia factor 1-interacting proteins (MLF1IP) in secondary endocrine resistance in Luminal breast cancer.
  • To elucidate the molecular mechanism by which MLF1IP contributes to Tamoxifen resistance.

Main Methods:

  • Cell Counting Kit-8 (CCK-8) assay to assess drug sensitivity.
  • Flow cytometry (FCM) to analyze apoptosis.
  • Western blot to detect apoptosis-related proteins and the PI3K/AKT signaling pathway.

Main Results:

  • Downregulation of MLF1IP increased drug sensitivity and inhibited proliferation of MCF-7 cells.
  • MLF1IP downregulation led to increased expression of BAX, Caspase3, Caspase7, and Caspase9.
  • Inhibition of MLF1IP increased PTEN expression and decreased p-AKT, suggesting PI3K/AKT pathway modulation.

Conclusions:

  • MLF1IP-mediated apoptosis resistance is key to secondary resistance in breast cancer.
  • MLF1IP promotes AKT phosphorylation by inhibiting PTEN, activating the PI3K/AKT pathway and causing resistance.
  • MLF1IP serves as a predictive factor for endocrine resistance in Luminal breast cancer.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.4K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.0K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.2K